DEA Gives CBD Derived Pharmaceutical, Epidiolex, Approval as a Schedule V Drug

The Drug Enforcement Administration (DEA) has given the Cannabidiol (CBD) derived pharmaceutical product, Epidiolex, a reported Schedule V status. The newly approved drug is an oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

The CBD product Epidiolex is derived from the cannabis plant and will be available to patients 2 years old or older suffering from these syndromes that product seizures. Epidiolex is manufactured and produced by public company GW Pharmaceuticals (NASDAQ: GWPH) who has seen a recent spike in their stock price since the FDA had approved the products for patients in the United States earlier this year.

A Schedule V status under the DEA states, “Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics.”

Recently, the FDA conducted a series of randomized clinical trials with patients suffering from these diseases that found that Epidiolex was successful in the reduction of seizures. Cannabidiol is non-psychoactive and can be extracted from both the cannabis and industrial hemp plants. It has shown to be effective in the reduction of anxiety, depression, inflammation, seizures, Alzheimer’s, and a number of different ailments.

Related posts

Industrial Hemp Pilot Program Reappears in the Missouri Legislature


The Cannabis Act in Canada will Revolutionize the Industrial Hemp Farming Industry


New York Calls on Banking Institutions to Work with Cannabis Businesses


Leave a Comment